Kyowa Kirin Co., Ltd. (OTCMKTS:KYKOF – Get Free Report) dropped 0.7% during trading on Wednesday. The stock traded as low as $14.40 and last traded at $14.40. Approximately 1,294 shares traded hands during mid-day trading, a decline of 89% from the average daily volume of 12,097 shares. The stock had previously closed at $14.50.
Analyst Ratings Changes
Separately, Jefferies Financial Group cut shares of Kyowa Kirin to a “hold” rating in a research report on Tuesday, September 8th. One analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Kyowa Kirin has a consensus rating of “Reduce”.
View Our Latest Stock Analysis on KYKOF
Kyowa Kirin Trading Down 1.0%
Kyowa Kirin Company Profile
Kyowa Kirin Co, Ltd. is a Japan-based pharmaceutical company that develops and commercializes innovative medicines, with a focus on specialty and rare diseases. Its research activities span oncology, immunology, allergy, nephrology, and other areas where significant unmet medical needs remain. The company uses technologies including antibody engineering and other biopharmaceutical approaches, as well as small-molecule drug development.
Kyowa Kirin’s products include Crysvita (burosumab), a treatment for certain rare disorders involving abnormal phosphate regulation, and Poteligeo (mogamulizumab), an antibody used in the treatment of particular forms of blood cancer.
Featured Stories
- Five stocks we like better than Kyowa Kirin
- Costco Ends Its Fiscal Year on a High Note, Eyes Big Expansion
- Cracker Barrel Stock Is Rallying Again, But the Turnaround Still Has a Traffic Problem
- Oracle’s Force Majeure Notice Exposes a Bigger Problem for the AI Build-Out
- Oil May Be Stronger Than It Looks—And Diamondback Is on Sale
Receive News & Ratings for Kyowa Kirin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kyowa Kirin and related companies with MarketBeat.com's FREE daily email newsletter.
